Compare Marvell Technology Inc (MRVL) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marvell Technology Inc vs Nuwellis Inc — how do they compare? Marvell Technology Inc trades at $270 (market cap $246.84B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: Marvell Technology Inc is far larger — about 112200× Nuwellis Inc's market cap, and Marvell Technology Inc pays a 0.09% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marvell Technology Inc for 42 Days and Nuwellis Inc for 26 Days on average.
| MRVL | NUWE | |
|---|---|---|
Market Cap | $246.84B | $2.20M |
Volume | 29,003,830 | 121,544 |
Sector | Technology | Health |
52-Week High | $316.43 | $146.65 |
52-Week Low | $73.73 | $0.68 |
Typical Hold Time | 42 Days | 26 Days |
Enterprise Value | $248.19B | -$1.52M |
Dividend Yield | 0.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marvell Technology (MRVL) trades at $284.68, down 0.81% on the day, with a bullish technical signal from moving averages and strong analyst support. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 expected at $1.1. Revenue growth is accelerating, driven by data center and custom AI chip demand, though current valuations are elevated with a P/E of 90.95. Recent news highlights a major Google deal and raised fiscal 2028 revenue guidance to $18 billion.
The outlook remains positive given robust AI infrastructure spending and management's optimistic forecasts. Key risks include high valuation multiples, competitive pressures, and execution challenges in scaling custom chip production. Analyst consensus is strongly bullish with a $327.86 price target, suggesting significant upside potential if growth targets are met.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
